Rigel Pharmaceuticals, Inc. (RIGL) Reports In-Line Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $50.36 -0.34%
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
INM, TRI, CRVL, More
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q1 EPS of ($0.25), in-line with the analyst estimate of ($0.25).
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Coinbase stock climbs as analysts maintain support
- Evercore Names New Top Pick: This Fashion Stock Joins Top 5 Outperformers
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
